Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biotech company Aeglea nets $51mm in IPO

Executive Summary

Biotech company Aeglea Biotherapeutics Inc. netted $51mm through the sale of 5.5mm common shares (including 481.9k over-allotment shares; partial exercise) at $10 in its IPO (up-sized from 3.5mm share filing but priced on low end; originally filed for maximum price of $18). The company previously raised $44mm in a Series B round in March 2015 with investments from Lilly Ventures, Novartis Venture Fund, and the University of Texas Horizon Fund.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies